LJP 394 suppressor of double-strand DNA antibodies data

LJPC reported additional Phase II findings at the meeting of the American College of Rheumatology in Orlando, Fla. The agent gave improved indicators of kidney disease

Read the full 264 word article

How to gain access

Continue reading with a
two-week free trial.